Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype.
暂无分享,去创建一个
Giorgio Palù | Maurizio Zazzi | Robert W Shafer | Cristina Parolin | R. Shafer | M. Zazzi | G. Palù | C. Reid | C. Parolin | Caroline Reid | Laura Romano | G. Venturi | L. Romano | P. E. Valensin | Giulietta Venturi | Federico Dal Bello | Pier E Valensin | F. Dal Bello
[1] F. Heinz,et al. Comparison of virtual phenotype and HIV‐SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains , 2002, HIV medicine.
[2] V. Calvez,et al. Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial , 2001, Antiviral therapy.
[3] B. Schmidt,et al. Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy. , 2002, AIDS reviews.
[4] Michael S Saag,et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.
[5] John Rockfeller McCormick Memorial Fund. Journal of infectious diseases , 1997 .
[6] J. Montaner,et al. Discrepant results in the interpretation of HIV‐1 drug‐resistance genotypic data among widely used algorithms , 2003, HIV medicine.
[7] R. Haubrich,et al. Phenotypic and Genotypic Resistance Assays: Methodology, Reliability, and Interpretations , 2001, Journal of acquired immune deficiency syndromes.
[8] S. Hammer,et al. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine , 2000, AIDS.
[9] Christos J. Petropoulos,et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.
[10] D. Kuritzkes,et al. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates. , 2001, The Journal of infectious diseases.
[11] D. Kempf,et al. Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy , 2001, Antiviral therapy.
[12] Bradley J. Betts,et al. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database , 2000, Nucleic Acids Res..
[13] Brendan Larder,et al. A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.
[14] H. Fleury,et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. , 1999, AIDS.
[15] D. Katzenstein,et al. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. , 2002, Journal of acquired immune deficiency syndromes.
[16] Bryan Chan,et al. Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..
[17] C. Tinelli,et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. , 2003, Journal of acquired immune deficiency syndromes.